News
ASCO: Novartis touts Kisqali adjuvant breast cancer data
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte
Views & Analysis
Sales & Marketing
Sponsored
How to cultivate a successful omnichannel strategy
In today's fast-paced digital world delivering relevant, valuable content that resonates with your target audience is more important than ever.
Market Access
Market Access 2023
Getting the right treatment, to the right patient, at the right time is the backbone of market access.
Sales & Marketing
Sponsored
Coaching Never Sleeps
Coaching has developed into one of the most powerful tools in a fast-changing pharmaceutical sector.
Sales & Marketing
Sponsored
Empowering MSLs to be the kings of Pharma’s New Frontier
The demand for high-calibre, sharply-focussed clinical knowledge and data is increasing as HCPs streamline and recalibrate their engagements with the pharmaceutical sector.
R&D
Partner Content
Welcome to the 5th TIL Therapies Summit!
The first commercial TIL therapy is brewing at Iovance, along with various clinical readouts which are set to come to fruition in 2023, along with the 5th TIL Therapies Summit whic
R&D
Partner Content
2nd Process Development for Cell Therapies
View the program here
Category :
Views & Analysis
/
